Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Implant Sciences

This article was originally published in The Gray Sheet

Executive Summary

Stock from recent initial public offering is accepted for listing on the American exchange under the symbol "IMX." Warrants will trade under the symbol "IMX.WS." Net proceeds from the firm's June 24 1 mil.-unit at $7.50 each increased to about $7.4 mil. with the recent exercise of the underwriters overallotment option for 138,000 additional units (1"The Gray Sheet" July 5, p. 27). The issue was initially traded on the Nasdaq and Boston stock exchanges, however, Amex trading is anticipated to add "heightened visibility, a potentially larger investor base and a more liquid auction market," Implant Sciences predicts

You may also be interested in...

Implant Sciences

Initial public offering of 1 mil. units at $7.50 each is effective June 25, with trading beginning on the Nasdaq smallcap market and the Boston Stock Exchange. Each unit consists of one share of common stock and one redeemable common stock purchase warrant. The Wakefield, Massachusetts firm recently received 510(k) clearance for its I-Plant iodine-125 radioactive seed for the treatment of prostate cancer and plans to use the IPO proceeds to ramp up production and staff, expand R&D, increase sales and marketing efforts, and for general corporate purposes. Implant Sciences, which develops products and processes for use of ion implantation and thin film coatings of radioactive and non-radioactive materials, also is working on radioactive coronary stents and interventional cardiology devices for prevention of restenosis. Westport Resources Investment Services was lead underwriter for the offering. Co-managers included Schneider Securities and Weatherly Securities Corporation

Finance Watch: Silverback, Kinnate, Sigilon Launch December’s First IPOs

Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.

BioCryst’s Oral Option To Take On Injectables In HAE Prophylaxis Market

Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts